{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T22:18:42Z","timestamp":1784931522527,"version":"3.55.0"},"reference-count":18,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T00:00:00Z","timestamp":1570752000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0223181","type":"journal-article","created":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T17:29:38Z","timestamp":1570814978000},"page":"e0223181","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":25,"title":["Lipid profile changings after switching from rilpivirine\/tenofovir disoproxil fumarate\/emtricitabine to rilpivirine\/tenofovir alafenamide\/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6622-6358","authenticated-orcid":true,"given":"Lucia","family":"Taramasso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1436-5089","authenticated-orcid":true,"given":"Antonio","family":"Di Biagio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Riccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Briano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Di Filippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Comi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Giacomini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Maggiolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,10,11]]},"reference":[{"key":"pone.0223181.ref001","unstructured":"Department of Health and Human Services (DHHS) 2018. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf. Accessed 25 March 2019."},{"key":"pone.0223181.ref002","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","article-title":"Tenofovir alafenamide: anovel prodrug of tenofovir for the treatment of human immunodeficiency virus","volume":"125","author":"AS Ray","year":"2015","journal-title":"Antivir Res"},{"key":"pone.0223181.ref003","first-page":"75","article-title":"A Comprehensive Development Agenda on Tenofovir Alafenamide in Clinical Practice.","volume":"20","author":"A Di Biagio","year":"2018","journal-title":"AIDS Rev"},{"key":"pone.0223181.ref004","first-page":"1163","article-title":"Treatment simplification to atazanavir\/ritonavir\u2009+\u2009lamivudine versus maintenance of atazanavir\/ritonavir\u2009+\u2009two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M).","volume":"72","author":"S Di Giambenedetto","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"pone.0223181.ref005","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ijantimicag.2016.07.009","article-title":"Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides","volume":"48","author":"A Di Biagio","year":"2016","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"pone.0223181.ref006","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1186\/s12879-018-3268-5","article-title":"Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA).","volume":"18","author":"L Taramasso","year":"2018","journal-title":"BMC Infect Dis"},{"issue":"4","key":"pone.0223181.ref007","doi-asserted-by":"crossref","first-page":"ofx239","DOI":"10.1093\/ofid\/ofx239","article-title":"Weight Gain: A Possible Side Effect of All Antiretrovirals.","volume":"4","author":"L Taramasso","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"pone.0223181.ref008","doi-asserted-by":"crossref","first-page":"e0171227","DOI":"10.1371\/journal.pone.0171227","article-title":"HIV drug therapy duration; a Swedish real world nationwide cohort study on InfCareHIV 2009\u20132014","volume":"12","author":"A H\u00e4ggblom","year":"2017","journal-title":"PLoS One"},{"key":"pone.0223181.ref009","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jinf.2017.01.012","article-title":"Real-world persistence with antiretroviral therapy for HIV in the United Kingdom: A multicentre retrospective cohort study","volume":"74","author":"JM Lewis","year":"2017","journal-title":"J Infect"},{"key":"pone.0223181.ref010","article-title":"First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate\/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate\/emtricitabine: a durability comparison","author":"L Taramasso","journal-title":"HIV Med."},{"key":"pone.0223181.ref011","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/hiv.12664","article-title":"Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials","volume":"19","author":"D Hagins","year":"2018","journal-title":"HIV Med"},{"key":"pone.0223181.ref012","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/bcpt.13161","article-title":"Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine","volume":"124","author":"P Cid-Silva","year":"2019","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"pone.0223181.ref013","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1089\/aid.2017.0064","article-title":"From Liguria HIV Web to Liguria Infectious Diseases Network: How a Digital Platform Improved Doctors' Work and Patients' Care","volume":"34","author":"B Giannini","year":"2018","journal-title":"AIDS Res Hum Retroviruses"},{"key":"pone.0223181.ref014","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"WT Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"pone.0223181.ref015","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/hiv.12664","article-title":"Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials","volume":"19","author":"D Hagins","year":"2018","journal-title":"HIV Med."},{"key":"pone.0223181.ref016","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1001\/archinte.161.22.2685","article-title":"Total cholesterol\/HDL cholesterol ratio vs LDL cholesterol\/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study","volume":"161","author":"I Lemieux","year":"2001","journal-title":"Arch Intern Med"},{"key":"pone.0223181.ref017","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/cid\/ciy176","article-title":"Incomplete Recovery of CD4 Cell Count, CD4 Percentage, and CD4\/CD8 Ratio in Patients With Human Immunodeficiency Virus Infection and Suppressed Viremia During Long-term Antiretroviral Therapy","volume":"67","author":"Y Mutoh","year":"2018","journal-title":"Clin Infect Dis"},{"key":"pone.0223181.ref018","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1186\/s12879-019-4184-z","article-title":"Clusterization of co-morbidities and multi-morbidities among persons living with HIV: a cross-sectional study","volume":"19","author":"P Maggi","year":"2019","journal-title":"BMC Infect Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0223181","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T16:33:16Z","timestamp":1611505996000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0223181"}},"subtitle":[],"editor":[{"given":"Robert","family":"G\u00fcerri-Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,10,11]]},"references-count":18,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,10,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0223181","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,11]]}}}